TF and cancer: Although normally applied in the absence of cells, the adapted method relies on the presence of endogenous TF within the cancer-on-a-chip model, probably expressed on glioblastoma-derived EVs or on HUVECs by cancer cell-mediated proinflammatory cytokines.